Cargando…
Safety and immunogenicity of the killed bivalent (O1 and O139) whole-cell cholera vaccine in the Philippines
The killed bivalent (O1 and O139) whole cell oral cholera vaccine (OCV) (Shanchol™) was first licensed in India in 2009 and World Health Organization pre-qualified in 2011. We assessed the safety and immunogenicity of this OCV in the Philippines. This was a phase IV, single-arm, descriptive, open-la...
Autores principales: | Capeding, Maria Rosario Z., Gonzales, Maria Liza Antoinette M., Dhingra, Mandeep Singh, D'Cor, Naveena Aloysia, Midde, Venkat Jayanth, Patnaik, Badri Narayan, Thollot, Yaël, Desauziers, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975480/ https://www.ncbi.nlm.nih.gov/pubmed/28910563 http://dx.doi.org/10.1080/21645515.2017.1342908 |
Ejemplares similares
-
Bivalent oral cholera vaccine in participants aged 1 year and older in the Dominican Republic: A phase III, single-arm, safety and immunogenicity trial
por: Cordero De Los Santos, Lina, et al.
Publicado: (2018) -
Safety and immunogenicity of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine in adults and children in Vellore, South India
por: Raghava Mohan, Venkata, et al.
Publicado: (2019) -
Safety and immunogenicity of a new formulation of a pentavalent DTwP-HepB-Hib vaccine in healthy Indian infants–A randomized study
por: Aloysia D’Cor, Naveena, et al.
Publicado: (2023) -
Comparison of O-specific polysaccharide responses in patients following infection with Vibrio cholerae O139 versus vaccination with a bivalent (O1/O139) oral killed cholera vaccine in Bangladesh
por: Kaisar, M. Hasanul, et al.
Publicado: (2023) -
Immunogenicity of a Killed Bivalent (O1 and O139) Whole Cell Oral Cholera Vaccine, Shanchol, in Haiti
por: Charles, Richelle C., et al.
Publicado: (2014)